Interim Management Statement

WORLDWIDE HEALTHCARE TRUST PLC                         

      Interim Management Statement - 3 months to 30 June 2013 (unaudited)      

Worldwide Healthcare Trust PLC invests worldwide in a diversified portfolio of 
shares in pharmaceutical and biotechnology companies and related securities in 
 the healthcare sector with the objective of achieving a high level of capital 
                                    growth.                                    

During the 3 month period ended 30 June 2013 the Company's fully diluted net
asset value per share total return was +2.1% and the Company's share price
total return was +4.8%. The Company's benchmark, the MSCI World Health Care
Index measured in sterling terms on a total return basis rose by 2.8% in the
same period. During the period, exposure to Asia and Emerging markets increased
while the portfolio's European exposure was reduced. Exposure to North America
remained unchanged. At the stock level, Roche remains the portfolio's largest
holding and the weightings in Biogen Idec and Amgen were increased while those
in Pfizer and Sanofi were reduced. From the period-end to 13 August 2013, the
Company's fully diluted net asset value per share total return was +6.4% and
the Company's share price total return was +8.8%. The Company's benchmark, the
MSCI World Health Care Index measured in sterling terms on a total return basis
rose by 4.4% in the same period.

During the period under review the Company continued to reissue shares from
treasury at prices representing no more than a 4.9% discount to the prevailing
fully diluted cum income net asset value per share. A total of 328,408 shares
were reissued in the period raising £3.5m of new funds for the Company. In
addition a total of 125,231 new shares were issued during the period and to the
date of this report as a result of holders of subscription shares exercising
their subscription rights. The exercise price is 699p and the next subscription
date is 31 October 2013. The expiry date of the subscription shares is on 31
July 2014.

No shares were repurchased by the Company during the three month period and to
the date of this report and no shares are currently held by the Company in
treasury.

The Company paid a second interim dividend of 9.5p per share during the period
which, together with the first interim dividend already paid, made a total
dividend for the year ended 31 March 2013 of 16.5p per share (2012:17.5p per
share). The second interim dividend was paid on 5 July 2013 to ordinary
shareholders on the register of members on 7 June 2013. The associated
ex-dividend date was 5 June 2013.

During the period Mrs Sarah Bates joined the Board. A former Chairman of the
Association of Investment Trust Companies, she is currently Chairman or a
Director of a number of investment trust and other public companies. In
addition, she is Chairman of, or a member of a number of charitable and pension
fund investment committees.

At the Company's Annual General Meeting, held on 17 July 2013, all of the
resolutions were passed. Anthony Townsend retired from the Board at the
conclusion of the Annual General Meeting. The resolution proposed at a separate
meeting of holders of subscription shares on 29 July 2013 (the meeting having
been adjourned from 17 July 2013) was also passed.

Trust Characteristics

                            30 June 2013             31 March 2013             
                                                                               
Number of holdings          62                       59                        
                                                                               
Net assets (£m)             511.7                    499.9                     
                                                                               
Net yield                   1.6%                     1.6%                      
                                                                               
Gearing (AIC basis)         13%                      10%                       
                                                                               
Share price (p)             1048.00                  1009.00                   
                                                                               
NAV (p) -undiluted          1112.97                  1100.32                   
                                                                               
NAV (p) diluted: sub shares 1092.86                  1080.26                   
                                                                               
NAV (p) - fully diluted for -                        1079.78                   
                                                                               
sub shares and treasury                                                        
shares                                                                         
                                                                               
Discount (undiluted)        5.8%                     8.3%                      
                                                                               
Discount (diluted - sub     4.1%                     6.6%                      
shares)                                                                        
                                                                               
Discount (fully diluted)    4.1%                     6.6%                      
                                                                               
Subscription share price    341.00                   307.50                    
(p)                                                                            

Source: Frostrow Capital LLP

10 Largest Investments

Name                       % of                      % of                      
                                                                               
                           portfolio                 portfolio                 
                                                                               
                           at 30 June 2013           at 31 March 2013          
                                                                               
Roche                      8.2                       9.0                       
                                                                               
Gilead Sciences            4.6                       4.6                       
                                                                               
Biogen Idec                4.1                                  1.3            
                                                                               
Amgen                      3.6                       3.0                       
                                                                               
Sanofi                     3.5                       4.2                       
                                                                               
HCA                        3.2                       3.8                       
                                                                               
Mylan                      3.1                       3.0                       
                                                                               
Bristol-Myers Squibb       2.9                       3.3                       
                                                                               
Merck & Co                 2.7                       2.7                       
                                                                               
Thermo Fisher Scientific   2.7                       0.9                       
                                                                               
                           38.6                      35.8                      

Source: Frostrow Capital LLP

Sector Analysis

                           % of                      % of                      
                                                                               
                           portfolio                 portfolio                 
                                                                               
                           at 30 June 2013           at 31 March 2013          
                                                                               
Large capitalisation       67.5                      71.5                      
                                                                               
Small capitalisation       32.5                      28.5                      
                                                                               
Total                      100.0                     100.0                     

Source: Frostrow Capital LLP

Geographical Analysis

                           % of                      % of                      
                                                                               
                           portfolio                 portfolio                 
                                                                               
                           at 30 June 2013           at 31 March 2013          
                                                                               
North America              63.3                      63.3                      
                                                                               
Europe                     16.8                      19.3                      
                                                                               
Asia                       8.1                       7.7                       
                                                                               
Emerging Markets           11.8                      9.7                       
                                                                               
Total                      100.0                     100.0                     

Source: Frostrow Capital LLP

Total Return Performance

                3 Months        1 Year          3 Years         5 Years        
                                                                               
Share price     +4.8            +30.7           +74.1           +155.2         
                                                                               
NAV Fully       +2.1            +25.8           +67.3           +142.7         
diluted                                                                        
                                                                               
Benchmark*      +2.8            +30.9           +71.7           +124.2         

Source: NAV (total return; fully diluted) and Share Price (total return)
Morningstar. Benchmark - Bloomberg and Thomson Reuters

* With effect from 1 October 2010, the performance of the Company is measured
against the MSCI World Health Care Index measured on a total return basis in
sterling terms. Prior to this date, performance was measured against the
Datastream World Pharmaceutical and Biotechnology Index on a total return basis
in sterling terms. Historic data, therefore, consists of a blended figure
containing both indices.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide
information to meet the requirements of the UK Listing Authority's Disclosure
and Transparency Rules.

This Interim Management Statement is available on the Company's website 
www.worldwidewh.com.

The Company's net asset value per share is announced daily and is available,
together with the share price, on the TrustNet website at www.trustnet.com

Identification Codes:

Ordinary Shares

SEDOL- 0338530

ISIN - GB0003385308

Bloomberg - WWH LN

EPIC - WWH

Subscription Shares

SEDOL - B3VMCB0

ISIN - GB00B3VMCB07

Bloomberg - WWHS LN

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

14 August 2013